Canada’s Ovarian Cancer diagnostics and therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.
Ovarian cancer is the 9th most commonly diagnosed cancer among Canadian women, is the 5th most common cause of death from cancer among women, and has the highest mortality rate of all cancers of the female reproductive system. An estimated 3,100 Canadian women will be diagnosed with ovarian cancer in 2020. An estimated 1,950 will die from the disease. Canada is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing prevalence of ovarian cancer.
Market Driving Factors
The driving factors for the growth of the Ovarian Cancer diagnostics and therapeutics market in Canada include rising prevalence, persistent investment in R&D, increasing geriatric women population, and government funding for research activities. To date 6M USD has been allocated for research by Ovarian Cancer Canada. 10M USD also allocated to advance progress on ovarian cancer research in Canada The increasing geriatric women population and prevalence of ovarian cancer and greater use of combination therapies for the treatment of ovarian cancer can be seen as primary drivers for the growth of this market.